NasdaqGS:CRBUBiotechs
Caribou Biosciences (CRBU): Revisiting Valuation Following Promising Phase 1 Clinical Trial Results
Caribou Biosciences (CRBU) is attracting fresh attention after releasing positive interim data from phase 1 trials of its lead CAR-T therapies, vispacabtagene regedleucel and CB-011, for lymphoma and multiple myeloma.
See our latest analysis for Caribou Biosciences.
Momentum has picked up for Caribou Biosciences following its positive clinical trial updates and upcoming pivotal studies, but recent volatility is hard to ignore. The stock’s 1-day share price return dropped 10.7% after the data...